Lupus Clinical Trials in District of Columbia

23 recruiting studies across 1 city

Browse by City

All Trials in District of Columbia

Phase

Trial	Phase	Sponsor	Dist.
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants	Phase 3	AstraZeneca	<1 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)	Phase 2	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	<1 mi
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions	—	Children's National Research Institute	<1 mi
Research Accelerated by You Lupus Registry	—	Lupus Foundation of America	<1 mi
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus	Phase 3	AstraZeneca	<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer	Phase 1	National Cancer Institute (NCI)	<1 mi
Patient-Centered Assessment of Symptoms and Outcomes	—	National Center for Complementary and Integrative Health (NCCIH)	6 mi
Study of Systemic Lupus Erythematosus	—	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	6 mi
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires	—	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	6 mi
Deciphering the Genetic Architecture of Autoimmune Diseases	—	National Human Genome Research Institute (NHGRI)	6 mi
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE	Phase 1/2	AstraZeneca	6 mi
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD	Phase 2	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	6 mi
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus	Phase 1/2	National Heart, Lung, and Blood Institute (NHLBI)	6 mi
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis	Phase 1	National Institute of Allergy and Infectious Diseases (NIAID)	6 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus	Phase 3	UCB Biopharma SRL	14 mi
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants	—	Bristol-Myers Squibb	14 mi
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Phase 3	Novartis Pharmaceuticals	15 mi
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)	—	Hospital for Special Surgery, New York	35 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V	Phase 2	Novartis Pharmaceuticals	35 mi
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus	Phase 3	AbbVie	35 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)	Phase 1	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	35 mi
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)	—	Ampel BioSolutions, LLC	35 mi
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus	Phase 3	Viatris Innovation GmbH	35 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.